- Home
- ELVA vs SKYE Comparison
ELVA vs SKYE Comparison
Compare ELVA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- SKYE
- Stock Information
- Founded
- ELVA 1996
- SKYE 2012
- Country
- ELVA Canada
- SKYE United States
- Employees
- ELVA 97
- SKYE N/A
- Industry
- ELVA
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- SKYE Health Care
- Exchange
- ELVA Nasdaq
- SKYE Nasdaq
- Market Cap
- ELVA 103.8M
- SKYE 80.7M
- IPO Year
- ELVA N/A
- SKYE N/A
- Fundamental
- Price
- ELVA $2.70
- SKYE $1.71
- Analyst Decision
- ELVA Strong Buy
- SKYE Buy
- Analyst Count
- ELVA 5
- SKYE 6
- Target Price
- ELVA $6.10
- SKYE $16.60
- AVG Volume (30 Days)
- ELVA 23.9K
- SKYE 1.7M
- Earning Date
- ELVA 05-14-2025
- SKYE 05-08-2025
- Dividend Yield
- ELVA N/A
- SKYE N/A
- EPS Growth
- ELVA N/A
- SKYE N/A
- EPS
- ELVA N/A
- SKYE N/A
- Revenue
- ELVA $43,693,000.00
- SKYE N/A
- Revenue This Year
- ELVA $55.29
- SKYE N/A
- Revenue Next Year
- ELVA $63.69
- SKYE N/A
- P/E Ratio
- ELVA N/A
- SKYE N/A
- Revenue Growth
- ELVA N/A
- SKYE N/A
- 52 Week Low
- ELVA $1.67
- SKYE $1.14
- 52 Week High
- ELVA $3.54
- SKYE $13.49
- Technical
- Relative Strength Index (RSI)
- ELVA 56.56
- SKYE 51.10
- Support Level
- ELVA $2.66
- SKYE $1.70
- Resistance Level
- ELVA $2.85
- SKYE $2.30
- Average True Range (ATR)
- ELVA 0.12
- SKYE 0.20
- MACD
- ELVA 0.01
- SKYE 0.03
- Stochastic Oscillator
- ELVA 50.00
- SKYE 52.94
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.